In this biography
Quick facts
- Born
- 1948
- Birthplace
- New Castle, Pennsylvania, United States
- Country
- United States
- Nationality
- Not independently established
- Known for
- Linking HER2 amplification with breast-cancer prognosis and helping develop antibody-based clinical research
Why this life matters
His work makes a useful distinction between learning which tumours have a worse prognosis and testing whether an intervention changes patient outcomes.
Timeline
Key moments
Birth in Pennsylvania
Born in New Castle.
Medical and research training
Completed his MD and PhD at the University of Chicago.
Prognostic study
Co-authored a study of HER2 amplification in primary breast cancers.
Clinical comparison
Co-authored a randomised antibody-plus-chemotherapy report.
Medicine and laboratory questions
Dennis Slamon was born in New Castle, Pennsylvania, in 1948. He studied at Washington and Jefferson College before completing an MD and a doctorate at the University of Chicago in 1975. An interview-based UCLA account describes scientific mentors who shaped his interest in research alongside clinical medicine. His subsequent training included residency and a UCLA fellowship. These steps help explain a career concerned with bringing observations about tumour biology into the questions an oncologist asks about patients and treatment.
A prognostic association came first
A 1987 Science paper by Slamon and colleagues examined HER2/neu in primary breast cancers. Its abstract associated gene amplification with relapse and survival, including analyses accounting for other recognised prognostic factors. The study was an important molecular comparison, but it did not randomly assign an antibody treatment. This distinction is central to his biography: identifying a characteristic linked with an outcome and demonstrating that an intervention changes that outcome are related achievements requiring different evidence.
Sources for this section: [4]
The intervention required another collaboration
A 2001 clinical report compared chemotherapy alone with chemotherapy plus trastuzumab in women with HER2-overexpressing metastatic breast cancer. The abstract reports both beneficial outcomes and important cardiac adverse effects. The development story therefore should not be reduced to a medicine that affects only malignant cells without consequences elsewhere. UCLA’s account of the 2019 Lasker recognition names Slamon alongside H. Michael Shepard and Axel Ullrich, preserving the antibody-development collaboration behind the more familiar individual biography.
Following a question across settings
Slamon and Brian Druker shared the 2019 Sjöberg Prize for work connecting molecular findings with cancer treatment. The comparison highlights a broader contribution: a biological clue becomes clinically meaningful through additional experiments, selected patient populations and carefully defined outcomes. In Slamon’s case, the research path moved from tumour characteristics to an intervention study. Readers can recognise that importance while preserving the limits of each dated publication. The earlier association did not establish every later benefit, and the later selected trial did not describe every form or stage of breast cancer.
Quick answers
Frequently asked questions about Dennis Slamon
- What is Dennis Slamon known for?
- Linking HER2 amplification with breast-cancer prognosis and helping develop antibody-based clinical research.
Keep exploring
Lives connected to this story
- Brian Druker
Compare another molecularly directed research programme and its clinical endpoints.
- Ruth Sager
Compare expression and behavioural observations in a separate laboratory programme.
Sources and further reading
Explore the evidence
These references support the biography and offer further reading. Official records, first-person accounts and independent reporting provide different perspectives; image records document attribution and licensing.
- 1. UCLA HealthDennis Slamon
Education and historical career:1975 MD/PhD, residency and UCLA fellowship. Present-tense leadership titles are not used as independently verified current appointments.
- 2. UCLA HealthMedicine in his DNA: a conversation with Dennis Slamon
Interview-based account of NewCastle upbringing, WashingtonandJefferson education and scientific mentors WinstonAnderson and WernerKirsten.
- 3. Royal Swedish Academy of SciencesTargeted treatment of cancer receives the Sjöberg Prize
Dated2019 award record confirms birth in NewCastle in1948,1975 degrees and joint recognition with BrianDruker. Historical professor title not treated as current.
- 4. Science / PubMedHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Complete1987 primary abstract:189 primary tumours, amplification and association with relapse/survival after adjustment; no treatment randomisation in that study.
- 5. NEJM / PubMedUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Complete2001 primary abstract in MEDLINE format:469 women with HER2-overexpressing metastatic disease, randomised chemotherapy with/without trastuzumab, progression/response/survival and cardiac adverse effects.
- 6. UCLA HealthUCLA oncologist Dennis Slamon wins2019 Lasker Award
Award recipients H.MichaelShepard,AxelUllrich and Slamon. Promotional broad claims about mutation and unharmed normal cells are not adopted.
